Design Therapeutics, Inc. (DSGN) stock
DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.84−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $615.80MP/E –Yield –
Design Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Design Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $58.78M, up 6.6% year over year. For fiscal 2025 it was $59.13M, up 33.3% from the year before. The highest annual figure on record is $59.13M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.13M | +33.3% |
| FY2024 | Dec 31, 2024 | $44.35M | -22.3% |
| FY2023 | Dec 31, 2023 | $57.06M | +17.4% |
| FY2022 | Dec 31, 2022 | $48.61M | +96.2% |
| FY2021 | Dec 31, 2021 | $24.78M | +308.9% |
| FY2020 | Dec 31, 2020 | $6.06M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.39M | +4.1% |
| Q1 FY2026 | Mar 31, 2026 | $14.38M | -6.5% |
| Q4 FY2025 | Dec 31, 2025 | $13.43M | +10.4% |
| Q3 FY2025 | Sep 30, 2025 | $14.59M | +22.8% |
| Q2 FY2025 | Jun 30, 2025 | $15.74M | +49.7% |
| Q1 FY2025 | Mar 31, 2025 | $15.38M | +56.9% |
| Q4 FY2024 | Dec 31, 2024 | $12.16M | +10.4% |
| Q3 FY2024 | Sep 30, 2024 | $11.88M | -10.4% |
| Q2 FY2024 | Jun 30, 2024 | $10.52M | -38.4% |
| Q1 FY2024 | Mar 31, 2024 | $9.80M | -37.7% |
| Q4 FY2023 | Dec 31, 2023 | $11.01M | -22.7% |
| Q3 FY2023 | Sep 30, 2023 | $13.26M | -7.3% |
| Q2 FY2023 | Jun 30, 2023 | $17.06M | +51.1% |
| Q1 FY2023 | Mar 31, 2023 | $15.73M | +79.6% |
| Q4 FY2022 | Dec 31, 2022 | $14.26M | +94.3% |
| Q3 FY2022 | Sep 30, 2022 | $14.30M | +67.5% |
| Q2 FY2022 | Jun 30, 2022 | $11.30M | +124.7% |
| Q1 FY2022 | Mar 31, 2022 | $8.76M | +126.0% |
| Q4 FY2021 | Dec 31, 2021 | $7.34M | +170.9% |
| Q3 FY2021 | Sep 30, 2021 | $8.54M | +346.1% |
| Q2 FY2021 | Jun 30, 2021 | $5.03M | +373.8% |
| Q1 FY2021 | Mar 31, 2021 | $3.88M | +927.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.71M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.91M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.06M | – |
| Q1 FY2020 | Mar 31, 2020 | $377.00K | – |
See a number that looks wrong?